VIENNA — The highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients with active rheumatoid arthritis to meet American College of Rheumatology (ACR) response ...

Aclaris Therapeutics has touted the latest phase 2 results for its “soft” JAK 1/3 inhibitor as a win for the beleaguered biotech, but investors appeared less enthusiastic about the wider set of mixed ...

Please provide your email address to receive an email when new articles are posted on . JAK inhibition carried higher malignancy risk vs. biologic DMARDs. Malignancy risk was seen in older patients ...

JAK inhibitors, a new class of tsDMARDs, have shown superior efficacy in RCTs for RA compared to other biologics. Real-world studies highlight JAK inhibitors' benefits in clinical disease activity, ...

NEW YORK CITY — When data from clinical trials of JAK inhibitors in atopic dermatitis (AD), vitiligo, and other skin diseases are stratified by race, response rates appear to diverge, with both higher ...